Perospirone

Perospirone
Systematic (IUPAC) name
	(3aR,7aS)-2-{4-[4-(1,2-benzisothiazol-3-yl)piperazin-1-yl]butyl}hexahydro-1H-isoindole-1,3(2H)-dione
Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy cat.	?
Legal status	℞ Prescription only
Routes	Oral
Pharmacokinetic data
Half-life	2-2.5 hours
Identifiers
CAS number	150915-41-6
ATC code	None
PubChem	CID 115368
ChemSpider	16737064
UNII	N303OK87DT
Chemical data
Formula	C23H30N4O2S
Mol. mass	426.57 g/mol
SMILES	eMolecules & PubChem
	InChI InChI=1S/C24H32N4O2S/c29-23-20-9-3-4-10-21(20)24(30)28(23)12-6-5-11-26-13-15-27(16-14-26)22-19-8-2-1-7-18(19)17-31-25-22/h1-2,7-8,20-21H,3-6,9-17H2/t20-,21+ ; Key:GTAIPSDXDDTGBZ-OYRHEFFESA-N ;
(what is this?) (verify);

From Wikipedia, the free encyclopedia

Jump to: navigation, search

Perospirone (Lullan) is an atypical antipsychotic of the azapirone chemical class.^[1] It was introduced in Japan in 2001 by Dainippon Sumitomo Pharma for the treatment of schizophrenia and acute bipolar mania.^[2]^[3] Perospirone acts as a 5-HT_1A receptor partial agonist, 5-HT_2A receptor inverse agonist, and D₂, D₄, and α₁-adrenergic receptor antagonist.^[4]^[5]^[6]^[7]

[edit] See also

Azapirone

[edit] References

^ Onrust SV, McClellan K (2001). "Perospirone". CNS Drugs 15 (4): 329–37; discussion 338. doi:10.2165/00023210-200115040-00006. PMID 11463136.
^ de Paulis T (January 2002). "Perospirone (Sumitomo Pharmaceuticals)". Current Opinion in Investigational Drugs (London, England : 2000) 3 (1): 121–9. PMID 12054062.
^ "Sumitomo Pharmaceuticals 2001 | News Release | Dainippon Sumitomo Pharma". http://www.ds-pharma.co.jp/english/news/sumitomo_2001/no_002.html.
^ Hirose A, Kato T, Ohno Y, et al. (July 1990). "Pharmacological actions of SM-9018, a new neuroleptic drug with both potent 5-hydroxytryptamine2 and dopamine2 antagonistic actions" (^{[dead link]}). Japanese Journal of Pharmacology 53 (3): 321–9. doi:10.1254/jjp.53.321. PMID 1975278. http://joi.jlc.jst.go.jp/JST.Journalarchive/jphs1951/53.321?from=PubMed.
^ Kato T, Hirose A, Ohno Y, Shimizu H, Tanaka H, Nakamura M (December 1990). "Binding profile of SM-9018, a novel antipsychotic candidate" (^{[dead link]}). Japanese Journal of Pharmacology 54 (4): 478–81. doi:10.1254/jjp.54.478. PMID 1982326. http://joi.jlc.jst.go.jp/JST.Journalarchive/jphs1951/54.478?from=PubMed.
^ Odagaki Y, Toyoshima R (2007). "5-HT1A receptor agonist properties of antipsychotics determined by [35SGTPgammaS binding in rat hippocampal membranes"]. Clinical and Experimental Pharmacology & Physiology 34 (5–6): 462–6. doi:10.1111/j.1440-1681.2007.04595.x. PMID 17439416. http://www3.interscience.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0305-1870&date=2007&volume=34&issue=5-6&spage=462.
^ Seeman P, Tallerico T (March 1998). "Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors". Molecular Psychiatry 3 (2): 123–34. doi:10.1038/sj.mp.4000336. PMID 9577836.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[pmid11463136-0] Onrust SV, McClellan K (2001). "Perospirone". CNS Drugs 15 (4): 329–37; discussion 338. doi:10.2165/00023210-200115040-00006. PMID 11463136.

[pmid12054062-1] Paulis T (January 2002). "Perospirone (Sumitomo Pharmaceuticals)". Current Opinion in Investigational Drugs (London, England : 2000) 3 (1): 121–9. PMID 12054062.

[urlSumitomo_Pharmaceuticals_2001_.7C_News_Release_.7C_Dainippon_Sumitomo_Pharma-2] "Sumitomo Pharmaceuticals 2001 | News Release | Dainippon Sumitomo Pharma". http://www.ds-pharma.co.jp/english/news/sumitomo_2001/no_002.html.

[pmid1975278-3] Hirose A, Kato T, Ohno Y, et al. (July 1990). "Pharmacological actions of SM-9018, a new neuroleptic drug with both potent 5-hydroxytryptamine2 and dopamine2 antagonistic actions" (^{[dead link]}). Japanese Journal of Pharmacology 53 (3): 321–9. doi:10.1254/jjp.53.321. PMID 1975278. http://joi.jlc.jst.go.jp/JST.Journalarchive/jphs1951/53.321?from=PubMed.

[pmid1982326-4] Kato T, Hirose A, Ohno Y, Shimizu H, Tanaka H, Nakamura M (December 1990). "Binding profile of SM-9018, a novel antipsychotic candidate" (^{[dead link]}). Japanese Journal of Pharmacology 54 (4): 478–81. doi:10.1254/jjp.54.478. PMID 1982326. http://joi.jlc.jst.go.jp/JST.Journalarchive/jphs1951/54.478?from=PubMed.

[pmid17439416-5] Odagaki Y, Toyoshima R (2007). "5-HT1A receptor agonist properties of antipsychotics determined by [35SGTPgammaS binding in rat hippocampal membranes"]. Clinical and Experimental Pharmacology & Physiology 34 (5–6): 462–6. doi:10.1111/j.1440-1681.2007.04595.x. PMID 17439416. http://www3.interscience.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0305-1870&date=2007&volume=34&issue=5-6&spage=462.

[pmid9577836-6] Seeman P, Tallerico T (March 1998). "Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors". Molecular Psychiatry 3 (2): 123–34. doi:10.1038/sj.mp.4000336. PMID 9577836.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

Dec	JAN	Feb
	25
2011	2012	2013

Perospirone

[edit] See also

[edit] References

Personal tools

Namespaces

Variants

Views

Actions

Search

Navigation

Interaction

Toolbox

Print/export

Languages